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Background: The use of standard chemotherapy regimens has changed the application of chemosensitivity tests
from all chemotherapy-eligible patients to those who have failed standard chemotherapy, which includes patients
with highly advanced, relapsed, or chemoresistant tumors.
Methods: We evaluated a total of 43 advanced primary and relapsed gastric cancers for chemosensitivity based on
drug dose response curves to improve the objectivity and quality of quantitative measurements. The dose response
curves were classified based on seven expected patterns. Instead of a binary chemosensitivity evaluation, we ranked
drug sensitivity according to curve shapes and comparison with the peak plasma concentration (ppc) of each drug.
Results: A total of 193 dose response curves were obtained. The overall informative rate was 67.4%, and 85.3% for
cases that had a sufficient number of cells. Paclitaxel (PXL)and docetaxel tended to show a higher rank, while
cisplatin (CIS) and 5-fluorouracil (5-FU) tended to show resistance, particularly among the 20 cases (46.5%) that had
recurrent disease after receiving chemotherapy with CIS and S-1 (5-FU). As such, we speculate that the resistant
pattern of the chemosensitivity test suggests that cells with acquired drug resistance were selected by
chemotherapy. Indeed, we observed a change in the chemosensitivity pattern of a sample before and after
chemotherapy in terms of PXL sensitivity, which was used after primary chemotherapy.
Conclusions: These results suggest that: (i) the dose–response pattern provides objective information for predicting
chemosensitivity; and (ii) chemotherapy may select resistant cancer cell populations as a result of the therapy.
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Standard chemotherapy for gastric cancer is considered
to have a significant treatment effect as evaluated by dis-
ease free survival (DFS) and overall survival (OS) [1-3].
Postoperative chemoradiotherapy for gastric cancer was
conducted in the United States with DFS and three-year
OS rates of 48% and 50%, respectively [4]. In Europe
and the United Kingdom, the result of the MAGIC trial
for perioperative chemotherapy was also significant [5].
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reproduction in any medium, provided the orS-1, an oral fluoropyrimidine, found an 80.1% three-year
OS and 72.2% DFS, which is now the standard of care
for postoperative Stage II/III patients [2]. However, des-
pite the implementation of standard adjuvant chemo-
therapy, the recurrence rate remains 30% to 40% within
five years of therapy [2,5-7]. Hence, highly advanced
chemo-naive primary cancers as well as relapsed tumors
after adjuvant chemotherapy are major subjects for che-
mosensitivity tests.
Most previous reports of chemosensitivity assays from
the 1990s demonstrated the utility of cell-based assays
to aid in the selection of drugs for treating advanced
cancers [8-10]. This was useful information for clinicians
because there was neither a consensus standard therapy
nor large-scale clinical trials established for advancedLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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scale clinical trials, some standard therapies for advanced
gastric cancer have been established [1-3]. Accordingly,
the indications for chemosensitivity tests have changed in
recent times because they are no longer urgently needed
for selecting first line therapies. Therefore, the chemosen-
sitivity test has become an approach that can determine
appropriate drugs for patients whose treatments fail or
who experience recurrence after standard therapies.
Rigid quantitation by conventional chemosensitivity as-
says has been quite challenging because the number of
available tumor cells from solid tumors is extremely lim-
ited, which precludes the construction of drug dose–
response curves from tumor cells [11,12]. The results
from a limited number of data points may not be of suffi-
cient quality for measuring the non-linear associations be-
tween drug dose and cell viability. In the present study,
chemosensitivity assays for gastric cancers are performed
on samples obtained from highly advanced lesions, from







Number % Number % Number %
Age, years
Median 59 53 68
Range 22 to 85 22 to 78 30 to 85
Sex
Male 30 69.8 15 68.2 15 71.4
Female 13 30.2 7 31.8 6 28.6
Stage a, b
II 2 4.7 0 0 2 9.5
IIIA 1 2.3 0 0 1 4.8
IIIB 5 11.6 1 4.5 4 19.0
IV 35 81.4 21 95.5 14 66.7
Histologyb
Intestinal 10 23.3 5 22.7 5 23.8
Diffuse 33 76.7 17 77.3 16 76.2
Stromab
Medullary type 5 11.6 0 0 5 23.8
Intermediate type 9 20.9 3 13.6 6 28.6
Scirrhous type 12 27.9 6 27.3 6 28.6
Unknown 17 39.5 13 59.1 4 19.0
Pre-therapy
Performed 30 69.8 16 72.7 14 66.7
Not performed 13 30.2 6 27.3 7 33.3
aAJCC (American Joint Commettee on Cancer)/UICC (Union for International
Cancer Control) classification.










Figure 1 Epithelial cell enrichment and defined dose–response
curve patterns. Epithelial cell enrichment by density gradient
centrifugation. (A) Crude cells from ascites taken from a patient with
peritonitis carcinomatosa. (B) Epithelial cells were enriched by
density gradient centrifugation. Six different drug dose–response
curve patterns (C): The left top panel represents a logistic curve
where sample cell growth is dominantly regulated by the drug
concentration. The middle top panel represents a hyperbolic curve
in which the drug does not suppress cell growth at all practical drug
concentrations. Horizontal and vertical axes represent drug
concentration and cell viability, respectively.
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samples will not affect the definitive pathological diagno-
sis. We consider the availability of a large number of cells
to be a substantial advantage in terms of quantitative mea-
surement of chemosensitivity.
Tumor cells from ascites are generally plentiful and seem
to have greater viability in primary culture compared to
cells from solid tumors. The availability of large numbers
of tumor cells provides the opportunity to quantify tumor
cell activity based on dose–response models. Hence, we
conducted a chemosensitivity assay that employs tumor
classification based on the patterns of dose response curves
obtained from multiple drug concentration points derived
from a sufficient number of tumor cells. Here we report the
results of a chemosensitivity assay with a dose–response
curve classification using specimens from highly advanced
tumors, with special focus on tumor cells obtained from
the ascites of patients with peritonitis carcinomatosa.
Methods
Patients
Forty-three gastric cancer patients who had either higher
than stage II disease or a recurrence were reviewed
(Table 1). Tumor samples were collected from patients after
written informed consent was obtained according to Insti-
tutional Review Board guidelines (H21-96, Iwate Medical
University). The test was approved by the Advanced Me-
dical Care categories of the Japanese Ministry of Labor and
Welfare.
Samples
Specimens from 21 primary solid gastric tumors and 22
ascites samples from peritonitis carcinomatosa patients
were obtained. Cells were immediately processed for theTable 2 Drugs used in chemosensitivity tests
Abbreviation Drug Mechanism of action
CIS cisplatin DNA synthesis inhibiti
5FU 5-fluorouracil Antimetabolite
CPT irinotecan Topoisomerase I inhib
SN38 SN-38 Topoisomerase I inhib
DTX docetaxel Microtubule inhibition
PXL paclitaxel Microtubule inhibition
MTX methotrexate Antimetabolite
DXR doxorubicin DNA synthesis inhibiti
EPI epirubicin DNA synthesis inhibiti
EPS etoposide Topoisomerase II inhib
GEM gemcitabine Antimetabolite
OXP oxaliplatin DNA synthesis inhibiti
VIN vinorelbin Microtubule inhibition
LEU leucovorin Anti metabolite
N.D., not determined; ppc, peak plasma concentration.chemosensitivity assay or stored at 4°C in serum-free
RPMI 1640 medium with heparin for up to six hours.
For primary tumors, specimens were minced and incu-
bated in an enzyme cocktail that included Hank’s
balanced salt solution (Sigma-Aldrich Co. LLC, Tokyo,
Japan), 7% sodium hydrogen carbonate (Otsuka Phar-
maceutical Co. Ltd, Tokyo, Japan), collagenase (Yakult,
Tokyo, Japan), deoxyribonuclease I, type IV (Sigma-
Aldrich Co.), and protease type XXV (Sigma-Aldrich
Co.), with rotation in a 37°C water bath for one hour
until the cells were separated [10]. Cells obtained from
ascites were centrifuged at 500 x g and the resulting cell
pellet was then treated with a Ficoll gradient solution to
separate the pellet into epithelial and non-epithelial cells
(Figure 1). After these steps, both primary and ascites
cells were counted and plated into a square flat-bottom
384 microtiter plate at a density of 5,000 to 10,000 cells/
well (450 to 900 cells/mm2) in serum-free RPMI 1640 in
a total volume of 70 μl. Cells were incubated for at least
24 hours before drug administration.
Anticancer agents
Fourteen anticancer agents were used in the assay
(Table 2). The starting concentration of all drugs was 1%
of the original vial (actual molar concentrations were
different). Each drug was added in a 10-fold dilution
series to confirm cell viability as a function of drug dose.
The peak plasma concentration (ppc) was used as a
reference in comparison with the 50% growth inhibitory
concentration (GI50: concentration of a drug for which
growth is reduced by 50% compared to the untreated
control) value, defined as the absorbance of water-
soluble tetrazolium (WST) salt, (Dojindo, Mashiki,
Japan) at which the growth was reduced by 50%Starting concentration (μM) ppc (μM)
on 1.67 × 10 8.33
3.84 × 103 1.17 × 102
ition 2.95 × 102 N.D.
ition 1.02 × 102 5.10 × 10-2
1.16 × 102 2.32
7.03 × 10 5.86
5.50 × 10 3.30 × 10
on 1.72 × 102 0.62
on 1.72 × 102 1.72 × 10
ition 3.40 × 102 1.69 × 10
3.34 × 103 7.34 × 10
on 1.26 × 102 2.27
9.3 × 10 0.93











































































































































Figure 2 Chemosensitivity rank. Frequency of drug expectation
rank based on GI50. (A) Ascites and (B) Solid tumors. (C) Frequency
of drug resistance defined by a hyperbolic pattern of dose–response
curves. GI50, concentration of a drug for which growth is reduced by
50% compared to the untreated control.
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has a unique ppc value, which is the indicator for evalu-
ating whether the effective drug concentration is achiev-
able in the human body. If the ppc is greater than the
GI50, then the drug is likely to affect cancer cell growth
in vivo.
Growth suppression assay
After 24 hours of drug exposure, 10% medium volume
(7 μl) of WST was added to each well of the primary
culture and incubated for 3 to 6 hours at 37°C supplemen-
ted with 5% CO2. Absorbance was measured at 450 nm
using a microplate reader (Tristar LB941, Berthold Tech-
nologies GmbH & Co. KG, Bad Wildbad, Germany).
Interpretation of dose–response curves
To facilitate the objective interpretation of dose–response
curves, we defined seven patterns that can be considered
to reflect the respective biological properties of primary
cultured cancer cells (Figure 2). When the curve is drug
concentration-dependent in a logistic fashion, the GI50
can be readily calculated as a logistic pattern. When cell
viability does not change across all concentrations except
for a steep drop at the highest dose, it is considered
‘hyperbolic’, which is a good indicator of drug resistance.
Other dose–response curves were eliminated from the
chemosensitivity evaluation, but categorization facilitates
diagnoses based on the curve-fitting concept. For logistic
curves, the GI50 can be compared with the ppc of each
drug to determine the chemosensitivity rank. The rank is
a relative ordering of the assay results in a given sample
and provides an idea of which drug is likely to have effi-
cacy towards the tumor. The curve fitting was performed
using a non-linear multiple regression analysis with Prism
software (Version 5.01, GraphPad Software, Inc., La Jolla,
CA, USA).
Evaluation of chemotherapeutic effect
For those samples where related information was avai-
lable, the chemotherapeutic effect on tumors in ascites
was evaluated by tumor markers, ascites volume, and
dietary intake. Although these evaluations are semi-
quantitative and often subjective, they may still be in-
formative in terms of the chemotherapeutic effect. The
qualitative evaluation criteria for pre- and post-
treatment tumor markers are as follows: Up, the marker
value is beyond the upper limit of the normal range
from within or below the normal range; Stable, the
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the normal range; and Down, the marker value goes
below the upper limit of the normal range from above
the normal range. Ascites volume was classified into the
following three groups: Up, Stable, and Down, which
were evaluated based on comprehensive clinical findings
including physical examination, ultrasonography, and
computed tomography. Dietary intake was classified into
Up, Stable, and Down categories by medical interview,
impression of health professionals, and chart review.
Results
Chemosensitivity test
A total of 43 gastric cancer specimens, including 22 from
ascites and 21 from solid tumors, were examined. A suffi-
cient number of cells for the WST assay was obtained in
34/43 (79%) cases, of which 16/22 (72%) cases were from
solid tumors and 18/21 (86%) were from ascites. Only one
out of 16 (6%) ascites cases was not analyzed due to low
viability, while four out of 18 (22%) solid tumors were not
analyzed due to fungal contamination (two cases), bacter-
ial contamination (one case), and low viability (one case).
Cells from each tumor sample were plated into wells of a
384-well microtiter plate and subsequently assayed with 3
to 16 drugs individually, each of which provided a dose–Table 3 Frequency of curve types
Curve Ty
Drug Logistic (%) Hyperbolic (%) Straight (%
CIS 9(9.7) 11(33.3) 0
5FU 5(5.4) 7(21.2) 3(33.3)
CPT 10(10.8) 3(9.1) 1(11.1)
SN38 11(11.8) 0(0.0) 0
DTX 18(19.4) 3(9.1) 1(11.1)
PXL 22(23.7) 1(3.0) 1(11.1)
OXP 3(3.2) 0(0.0) 0
EPS 3(3.2) 1(3.0) 0
GEM 1(1.1) 1(3.0) 0
5FU + LEU 0(0) 2(6.1) 0
CIS + 5FU 4(4.3) 3(9.1) 1(11.1)
MTX 3(3.2) 0 0
5FU + MTX 1(1.1) 0 1(11.1)
EPI 0 0 1(11.1)
CBP 0 1(3.0) 0
5FU + DTX 1(1.1) 0 0
5FU + SN38 1(1.1) 0 0
DXR 1(1.1) 0 0
VIN 0 0 0
Curve Fractionb 93(48.2) 33(17.1) 9(4.7)
a% indicates fraction per curve type; b% indicates fraction of all 193 curve types.response curve. Overall, 29 samples produced 193 dose–
response curves with one curve per drug per specimen
(Table 3). In ascites cases, we obtained 110 curves from 15
cases (7.3 drugs per specimen) and for solid tumor cases,
83 curves from 14 cases (5.9 drugs per specimen).
Interpretation of dose–response curve data
Each dose–response curve was categorized into one of the
six previously determined patterns. Two major patterns
(logistic and hyperbolic) represented 65% (126/193) of all
patterns. Logistic and hyperbolic patterns are considered
to be indicative of ‘drug-dependent cellular viability’ and
‘drug resistance’, respectively. In fact, 24.2% of hyperbolic
curves were from tumors that had been previously treated
with the corresponding drug. While we did not use curves
from other categories (67/193, 35%) for further analysis,
they were useful for interpreting curves and in particu-
lar helped minimize variations in interpretations by the
examiner.
The curves were further evaluated to rank the drugs
based on GI50 and ppc. From logistic curves, we calcu-
lated GI50 values to represent how effective the drug was
on the cells. GI50 values from 93 logistic curves were
compared with the corresponding drug’s ppc. Eighty-one
out of 93 (87%) curves showed that the ppc was greaterpesa
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ference between the ppc and GI50, the better the chance
that the drug is effective, we ranked the set of drugs
used for each assay.
Although the number of drugs tested for one sample
was inconsistent because the number of available cells
varied, paclitaxel (PXL) seemed to be most effective
(rank, 1), followed by docetaxel (DTX) (rank, 2) and cis-
platin (CIS) (rank, 3; Figure 3A and B). PXL showed the
highest average rank (rank, 1.29) for ascites (Figure 3A)
while CIS (rank, 1; Figure 3B) was the highest for solid
tumors.
Patient outcomes and chemosensitivity test
The number of evaluable cases was 15 for ascites. Two out
of the 15 cases were eliminated because of a marked de-
cline in general condition. The remaining 13 cases pro-
ceeded to systemic chemotherapy based on the results of
the chemosensitivity test. Thus, all chemosensitivity eva-
luations for 13 cases were based on drugs with a rank of 1
or 2 (Table 4). Tumor markers were decreased or stable in
7/13 (54%) and 11/13 (86%) patients for carcinoembryonic
antigen (CEA) and cancer antigen 19–9 (CA19-9), respect-
ively. Ascites volume showed a substantial decrease or
remained stable in 11/13 (85%) cases, indicating that asci-


































Figure 3 Replacement of cellular population by chemotherapy. Drug
patient who received two chemosensitivity tests, pre- and post-chemotherresponsive markers in highly advanced cases. Although
dietary intake is less objective than other parameters,
increased intake for 8/13 (62%) cases suggests a direct as-
sociation with the reduction of gastrointestinal burden and
minimum adverse effects by the selected chemotherapy.
Replacement of cellular population after chemotherapy
Although the number is limited, we had a pair of sam-
ples for which the patient received two chemosensitivity
tests, pre- and post-chemotherapy. Case GC-022 showed
CIS resistance (hyperbolic), while PXL ranked first in
the first chemosensitivity assay at pre-chemotherapy. As-
cites volume was increased nine weeks after completion
of six cycles of 80 mg/m2 PXL weekly. A subsequent
chemosensitivity assay (GC-025) on ascites demon-
strated a more than five-fold increase in GI50 PXL, but
they remained resistant to CIS (Figure 3).
Discussion
The utility of cell-based assays for evaluating chemosen-
sitivity depends on the quality of the quantitative pro-
cesses, because the number of cells, replicates, and
dilution series are critical for obtaining good measure-
ment quality [8-10]. The 384-well microtiter plate used
in the present study requires 5,000 to 10,000 cells per
































dose–response curves from a pair of samples from an individual
apy for CIS (A) and PXL (B).
Table 4 Evaluation of chemotherapy by tumor marker,
ascites volume, diet
Tumor Markers Cases % Responded
CEA
Up 6 (46%)








Stable 3 (23%) 85%
Down 8 (62%)
Diet
Up 8 (62%) 62%
Stable 0 (0%)
Down 5 (38%)
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points. The drug concentration-cell growth (that is,
dose–response) curve is generally not linear, and ideally
should be logistic. To evaluate drug sensitivity, the curve
must show a logistic curve that is considered to be a
pharmacological drug response [12,15]. We confirmed
that hyperbolic dose–response curves are a sufficient in-
dicator of drug resistance. Other curve types do not dir-
ectly indicate any clinical applications, but did help with
assay evaluation by multiple examiners in daily practice.
We determined the chemosensitivity rank based on re-
sponse expectancy instead of binary nominal sensitivity
(that is, sensitive or non-sensitive) [8-10]. Although the
rank depends on how many drugs are tested in a given
assay, PXL seems to be the most frequently highly-
ranked drug. CIS and 5-FU (that is, S-1, an oral fluoro-
pyrimidine), which had been the first choice for highly
advanced gastric cancer chemotherapy, seemed to have
lower ranks in post-treatment tumors, implying that the
tumors may have acquired drug resistance during pri-
mary chemotherapy. In primary chemo-naive tumors,
however, CIS showed good sensitivity, suggesting that
CIS is a reasonable choice as a first line drug for primary
tumors, as most regimens include this drug.
Although the number of cases is still limited, one of
the major benefits of the present approach is the ability
to see population changes in cancer cells at different
time points for a given patient. For instance, GC-022
and GC-025 are samples from a patient who was treated
with six cycles of 80 mg/m2 PXL weekly and showed a
five-fold increase in GI50 values for PXL, whileremaining resistant to CIS. It is reasonable to speculate
that the acquisition of drug resistance would be due to
changes in the tumor cell population [14]. Recent
reports demonstrated that genome-wide genetic and epi-
genetic events accumulate during cancer progression
[16]. Therefore, the phenotypic change we observed in
the present case suggests that drug-induced phenotypic
or genetic/epigenetic changes occurred during our rou-
tine cancer therapies [14].
The response rate of standard cancer therapies is still
generally around 30% to 40% [1-3]. To determine stand-
ard therapies based on tumors of origin through epigen-
etic studies, large-scale clinical trials are important.
However, continued efforts are necessary to minimize
the fraction of patients who would not benefit from the
standard therapy as well as to provide justification for
each type of therapy. The biological properties of cancer
cells are often drastically different depending on each
patient, so treatments should be flexible based on tumor
characteristics. Patients with ascites have very poor life
expectancy from the date of diagnosis and many fail ei-
ther standard or other subsequent therapies [17]. Our
chemotherapeutic response expectation rankings suggest
that it would be possible to make better drug choices
that may prolong survival and significantly decrease the
cancer burden for these patients [11].
Conclusions
Our chemosensitivity assay is still a conventional cell-
based technique. However, the assay can more accurately
determine appropriate drug regimens based on the
tumor response to drugs using a currently available and
reliable technique with a sufficient number of tumor
cells. The chemosensitivity assay is more applicable to
many types of chemotherapeutic drugs. Our present data
provide clues for profiling individual tumors based on
functional drug response information. As such, data ac-
cumulation and acquisition of supporting molecular evi-
dence is warranted.
Abbreviations
CA19-9: cancer antigen 19–9; CEA: carcinoembryonic antigen; CIS: cisplatin;
CPT: irinotecan; DFS: disease free survival; DXR: doxorubicin; DTX: docetaxel;
EPI: epirubicin; EPS: etoposide; GEM: gemcitabine; GI50: 50% growth
inhibitory concentration; LEU: leucovorin; MTX: methotrexate; N.D.: not
determined; OS: overall survival; OXP: oxaliplatin; ppc: peak plasma
concentration; PXL: paclitaxel; SN38: SN-38; VIN: vinorelbin; WST: water-
soluble tetrazolium; 5FU: 5-fluorouracil.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
TM carried out the chemosensitivity assay and drafted the manuscript; SSN
carried out the experimental design and drafted the manuscript; KI carried
out the chemosensitivity assay and experimental design; FE carried out the
chemosensitivity assay; HK carried out the chemosensitivity assay; KKu carried
out the chemosensitivity assay; MI carried out the chemosensitivity assay and
experimental design; KKo carried out the experimental design; GW carried
Matsuo et al. World Journal of Surgical Oncology 2013, 11:11 Page 8 of 8
http://www.wjso.com/content/11/1/11out the experimental design. All authors read and approved the final
manuscript.
Acknowledgements
Funding: Keiryokai Collaborative Research Support (SSN); Grant-in-Aid for
Scientific Research(C) (11863286) (SSN), and (12877914) (KKo)
Author details
1Laboratory of Molecular Therapeutics Iwate Medical University School of
Medicine, 19-1 Uchimaru, Morioka, Iwate 020-8505, Japan. 2Department of
Surgery Iwate Medical University School of Medicine, 19-1 Uchimaru,
Morioka, Iwate 020-8505, Japan. 3MIAST (Medical Innovation by Advanced
Science and Technology) Program, Iwate Medical University School of
Medicine, 19-1 Uchimaru, Morioka, Iwate 020-8505, Japan. 4Institute for
Biomedical Sciences, Iwate Medical University, 2-1-1 Nishitokuta, Yahaba,
Iwate 028-3694, Japan.
Received: 1 September 2012 Accepted: 6 January 2013
Published: 22 January 2013
References
1. Narahara H, Iishi H, Imamura H, Tsuburaya A, Chin K, Imamoto H, Esaki T,
Furukawa H, Hamada C, Sakata Y: Randomized phase III study comparing
the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line
treatment for advanced gastric cancer (study GC0301/TOP-002).
Gastric Cancer 2011, 14:72–80.
2. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A,
Furukawa H, Nakajima T, Ohashi Y, Imamura H, Higashino M, Yamamura Y,
Kurita A, Arai K: Adjuvant chemotherapy for gastric cancer with S-1, an
oral fluoropyrimidine. N Engl J Med 2007, 357:1810–1820.
3. Thuss-Patience PC, Kretzschmar A, Dogan Y, Rothmann F, Blau I, Schwaner I,
Breithaupt K, Bichev D, Grothoff M, Grieser C, Reichardt P: Docetaxel and
capecitabine for advanced gastric cancer: investigating dose-dependent
efficacy in two patient cohorts. Br J Cancer 2011, 105:505–512.
4. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC,
Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM,
Martenson JA: Chemoradiotherapy after surgery compared with surgery
alone for adenocarcinoma of the stomach or gastroesophageal junction.
N Engl J Med 2001, 345:725–730.
5. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ,
Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE,
Verma M, Weeden S, Chua YJ, MAGIC Trial Participants: Perioperative
chemotherapy versus surgery alone for resectable gastroesophageal
cancer. N Engl J Med 2006, 355:11–20.
6. Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T,
Nashimoto A, Fujii M, Nakajima T, Ohashi Y: Five-year outcomes of a
randomized phase III trial comparing adjuvant chemotherapy with S-1
versus surgery alone in stage II or III gastric cancer. J Clin Oncol 2011,
29:4387–4393.
7. Nashimoto A, Nakajima T, Furukawa H, Kitamura M, Kinoshita T, Yamamura
Y, Sasako M, Kunii Y, Motohashi H, Yamamoto S: Randomized trial of
adjuvant chemotherapy with mitomycin, Fluorouracil, and Cytosine
arabinoside followed by oral Fluorouracil in serosa-negative gastric
cancer: Japan Clinical Oncology Group 9206–1. J Clin Oncol 2003,
21:2282–2287.
8. Furukawa T, Kubota T, Watanabe M, Takahara T, Yamaguchi H, Takeuchi T,
Kase S, Kodaira S, Ishibiki K, Kitajima M, et al: High in vitro-in vivo
correlation of drug response using sponge-gel-supported three-
dimensional histoculture and the MTT end point. Int J Cancer 1992,
51:489–498.
9. Hoffman RM: In vitro sensitivity assays in cancer: a review, analysis, and
prognosis. J Clin Lab Anal 1991, 5:133–143.
10. Kawamura H, Ikeda K, Takiyama I, Terashima M: The usefulness of the ATP
assay with serum-free culture for chemosensitivity testing of
gastrointestinal cancer. Eur J Cancer 1997, 33:960–966.
11. Kubota T, Sasano N, Abe O, Nakao I, Kawamura E, Saito T, Endo M, Kimura K,
Demura H, Sasano H, et al: Potential of the histoculture drug-response
assay to contribute to cancer patient survival. Clin Cancer Res 1995,
1:1537–1543.
12. Yoshimasu T, Oura S, Hirai I, Tamaki T, Kokawa Y, Ota F, Nakamura R,
Shimizu Y, Kawago M, Hirai Y, Naito K, Kiyoi M, Tanino H, Okamura Y,Furukawa T: In vitro evaluation of dose–response curve for paclitaxel in
breast cancer. Breast Cancer 2007, 14:401–405.
13. Arteaga CL, Forseth BJ, Clark GM, Von Hoff DD: A radiometric method for
evaluation of chemotherapy sensitivity: results of screening a panel of
human breast cancer cell lines. Cancer Res 1987, 47:6248–6253.
14. Agarwal R, Kaye SB: Ovarian cancer: strategies for overcoming resistance
to chemotherapy. Nat Rev Cancer 2003, 3:502–516.
15. Richter L, Ruckert U, Kramer S: Learning a predictive model for growth
inhibition from the NCI DTP human tumor cell line screening data: does
gene expression make a difference? Pac Symp Biocomput 2006, :596–607.
16. Kim K, Chun KH, Suh PG, Kim IH: Alterations in cell proliferation related
gene expressions in gastric cancer. Crit Rev Eukaryot Gene Expr 2011,
21:237–254.
17. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K,
Nishizaki T, Kobayashi O, Takiyama W, Toh Y, Nagaie T, Takagi S, Yamamura
Y, Yanaoka K, Orita H, Takeuchi M: S-1 plus cisplatin versus S-1 alone for
first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III
trial. Lancet Oncol 2008, 9:215–221.
doi:10.1186/1477-7819-11-11
Cite this article as: Matsuo et al.: Evaluation of chemosensitivity
prediction using quantitative dose–response curve classification for
highly advanced/relapsed gastric cancer. World Journal of Surgical
Oncology 2013 11:11.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
